Cytosorbents Corporation
As of Oct 22, 2026, Cytosorbents is in Stage 4, the downtrend phase, now in week 29 (since Apr 2, 2026). It closed at $6.01, 64.6% below its 52-week high and below its 200-day average, which is falling.
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is CTSO early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
CTSO among Medical Devices98th of 141 by relative strength
All 141 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | TXG | Stage 2 · wk 48 | 99 | −7.8% |
| 2 | RCEL | Stage 2 · wk 13 | 98 | +40.8% |
| 3 | BFLY | Stage 2 · wk 26 | 98 | −26.0% |
| 4 | HAE | Stage 2 · wk 17 | 96 | +8.7% |
| 5 | GKOS | Stage 2 · wk 25 | 96 | +15.1% |
| 6 | AXGN | Stage 3 · wk 2 | 95 | −15.3% |
| 7 | NEOG | Stage 2 · wk 14 | 95 | −11.7% |
| 8 | BVS | Stage 2 · wk 15 | 95 | +10.5% |
| …98 | CTSO | Stage 4 · wk 29 | 17 | +22.4% |
Cytosorbents: quick answers
What stage is Cytosorbents in?
As of Oct 22, 2026, Cytosorbents (CTSO) is in Stage 4, the downtrend phase. It entered Stage 4 on Apr 2, 2026 and is in week 29. What the four stages mean
Is Cytosorbents in an uptrend?
No. Cytosorbents is in a Stage 4 downtrend. It trades 38.5% below its 200-day average, which is falling.
How far is Cytosorbents from its 52-week high?
Cytosorbents closed at $6.01 on Oct 22, 2026, 64.6% below its 52-week high of $17.00. Its 52-week low is $3.06.
How has Cytosorbents performed over the past year?
As of Oct 22, 2026, Cytosorbents is down 63.7% over the past year and down 54.2% so far in 2026.
Which sector and industry is Cytosorbents in?
Cytosorbents is in the Medical Devices industry, part of the Health Care sector.
About this companyHealth Care· Medical Devices
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications, as well as to remove antithrombotic drugs and inflammatory mediators in cardiothoracic surgery applications. The company also develops DrugSorb-ATR antithrombotic removal system, an investigational device to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs; ECOS-300CY to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system; VetResQ, a broad-spectrum blood purification adsorber for the treatment of septic shock, toxic shock syndrome, toxin-mediated diseases, pancreatitis, trauma, liver failure, heat stroke, and lung injury in animals; and PuriFi, an advanced hemoperfusion pump for blood purification therapies. In addition, it develops HemoDefend-BGA, a blood purification technology platform to reduce anti-A and anti-B antibodies in plasma and whole blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.